Multiple sclerosis and related disorders · 2026
Predicting clinical progression in patients with relapsing remitting multiple sclerosis retrospectively using a myelin content proxy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van den Boogaard Lis J M, Monachino Simone, Drenthen Gerhard S, Knippenberg Stephanie A M, Kreiter Daniel, Zinger Svitlana, Fernandes Catarina D, Breeuwer Marcel, Jolani Shahab, Jansen Jacobus F A, Gerlach Oliver H H
Аннотация
BACKGROUND: Progression independent of relapse- and magnetic resonance imaging (MRI)-activity (PIRMA) in relapsing-remitting multiple sclerosis (RRMS) may result from subtle myelin pathology in normal-appearing white matter (NAWM) and perilesions.
OBJECTIVE: To evaluate whether short-term myelin changes, estimated with the MRI-based T1w/FLAIR ratio, are associatied with long-term clinical progression in patients with RRMS receiving natalizumab.
METHODS: For 29 patients with RRMS, short-term, six-month myelin changes were calculated for three areas, i.e. white matter hyperintensities (WMH), a perilesional area of 2 mm, and NAWM. Expanded disability status scale (EDSS) scores at baseline and after at least three years were used to define long-term clinical progression.
RESULTS: Logistic regression models demonstrated significant associations between long-term progression using short-term changes in myelin proxy in NAWM (β = -77.962; p = .039), but not in perilesional tissue (β = -3.999; p = .717) and WMH (β = -4.324; p = .752). ROC-curve of the logistic regression model of NAWM showed a good discriminative value (area under the curve (AUC) = 0.892, 95% CI [.755-1.000]) for clinical progression.
CONCLUSION: By assessing short-term myelin changes outside lesions, using readily available clinical MRI scans, long-term clinical progression in patients with RRMS may be predicted.
OBJECTIVE: To evaluate whether short-term myelin changes, estimated with the MRI-based T1w/FLAIR ratio, are associatied with long-term clinical progression in patients with RRMS receiving natalizumab.
METHODS: For 29 patients with RRMS, short-term, six-month myelin changes were calculated for three areas, i.e. white matter hyperintensities (WMH), a perilesional area of 2 mm, and NAWM. Expanded disability status scale (EDSS) scores at baseline and after at least three years were used to define long-term clinical progression.
RESULTS: Logistic regression models demonstrated significant associations between long-term progression using short-term changes in myelin proxy in NAWM (β = -77.962; p = .039), but not in perilesional tissue (β = -3.999; p = .717) and WMH (β = -4.324; p = .752). ROC-curve of the logistic regression model of NAWM showed a good discriminative value (area under the curve (AUC) = 0.892, 95% CI [.755-1.000]) for clinical progression.
CONCLUSION: By assessing short-term myelin changes outside lesions, using readily available clinical MRI scans, long-term clinical progression in patients with RRMS may be predicted.